2024 - Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases

Globally, more than 20 million people are diagnosed with Alzheimer’s disease. Researchers have made tremendous progress in understanding Alzheimer’s disease pathology, resulting in a consensus on the biological definition of the disease. Novel blood-based biomarkers, such as pTau217 and Aβ 42/40, have also emerged.
Now, with the approval of Eisai and Biogen’s LeqembiTM and Lilly’s KisunlaTM, therapeutic development efforts by biopharma have been reinvigorated, and diagnostics are now enabled by available therapies. The shifting dynamics of therapeutic development in dementia and neurodegenerative disease treatment requires an understanding not only of the diseases themselves but also an understanding of the patient care continuum from diagnosis to treatment.
To fully realize the benefits of promising emerging biomarkers like Aβ 42/40 or pTau217, the global ecosystem for bringing these biomarkers into practical use in drug development and diagnostic environments must be considered.
In this webinar, the expert speakers discuss novel biomarkers relevant to Alzheimer’s disease and other neurodegenerative diseases and explore various platforms that support these biomarkers across a range of regulatory environments. They will bring real-life examples featuring innovative solutions and ecosystem partnerships that must be considered with global Alzheimer’s disease clinical trial approaches.
Join this webinar to learn more about how a holistic understanding of the disease pathology of Alzheimer’s disease, Lewy body dementia and more — in both diagnostics and drug development — can drive accelerated therapies to patients in need.
Keywords: Alzheimer's, Alzheimer's Disease, Drug Development, Neurodegenerative Disease, Biomarkers, Therapeutic Areas, CNS, Alzheimer's Disease Trials, Lewy Body Dementia, pTau217, biomarker-driven development